NS6180, a new K(Ca) 3.1 channel inhibitor prevents T-cell activation and inflammation in a rat model of inflammatory bowel disease.
about
K+ Channel Inhibition Differentially Regulates Migration of Intestinal Epithelial Cells in Inflamed vs. Non-Inflamed Conditions in a PI3K/Akt-Mediated MannerNovel phenolic inhibitors of small/intermediate-conductance Ca²⁺-activated K⁺ channels, KCa3.1 and KCa2.3Identification and Characterization of a Novel Association between Dietary Potassium and Risk of Crohn's Disease and Ulcerative ColitisTargeting potassium channels Kv1.3 and KC a 3.1: routes to selective immunomodulators in autoimmune disorder treatment?Expression of T-cell KV1.3 potassium channel correlates with pro-inflammatory cytokines and disease activity in ulcerative colitisA novel pan-negative-gating modulator of KCa2/3 channels, fluoro-di-benzoate, RA-2, inhibits endothelium-derived hyperpolarization-type relaxation in coronary artery and produces bradycardia in vivo.Blocking KCa3.1 channels increases tumor cell killing by a subpopulation of human natural killer lymphocytesThe Ca²⁺-activated K⁺ channel KCa3.1 as a potential new target for the prevention of allograft vasculopathy.Structural Insights into the Atomistic Mechanisms of Action of Small Molecule Inhibitors Targeting the KCa3.1 Channel Pore.Ion channels in innate and adaptive immunityDevelopment of a QPatch automated electrophysiology assay for identifying KCa3.1 inhibitors and activators.Endothelial small-conductance and intermediate-conductance KCa channels: an update on their pharmacology and usefulness as cardiovascular targets.Role of epithelial ion transports in inflammatory bowel disease.KCa3.1 (IK) modulates pancreatic cancer cell migration, invasion and proliferation: anomalous effects on TRAM-34.Potassium channel expression and function in microglia: Plasticity and possible species variations.KCa3.1 Channel Modulators as Potential Therapeutic Compounds for Glioblastoma.Assessing the role of IKCa channels in generating the sAHP of CA1 hippocampal pyramidal cells.Blood-brain barrier KCa3.1 channels: evidence for a role in brain Na uptake and edema in ischemic stroke.JMV5656, A Novel Derivative of TLQP-21, Triggers the Activation of a Calcium-Dependent Potassium Outward Current in Microglial Cells.Neuronal expression of the intermediate conductance calcium-activated potassium channel KCa3.1 in the mammalian central nervous system.Structural Determinants for the Selectivity of the Positive KCa3.1 Gating Modulator 5-Methylnaphtho[2,1-d]oxazol-2-amine (SKA-121).Senicapoc: Repurposing a Drug to Target Microglia KCa3.1 in Stroke.Quantification of the functional expression of the Ca2+ -activated K+ channel KCa 3.1 on microglia from adult human neocortical tissue.Upregulation of KCa3.1 K(+) channel in mesenteric lymph node CD4(+) T lymphocytes from a mouse model of dextran sodium sulfate-induced inflammatory bowel disease.Modafinil improves monocrotaline-induced pulmonary hypertension rat model.The Somatostatin Receptor-4 Agonist J-2156 Alleviates Mechanical Hypersensitivity in a Rat Model of Breast Cancer Induced Bone Pain.Histone Deacetylases Enhance Ca-Activated K⁺ Channel K3.1 Expression in Murine Inflammatory CD4⁺ T Cells
P2860
Q27324841-8AB84915-E7C5-4A92-8894-27308351750DQ28488052-E2D5FA65-5805-4247-84AC-2504C245CB60Q28589221-AF9C607D-5689-464B-9FAA-CEC615D743C7Q34343254-D05B8D44-0C40-433D-8159-FB022C2FDB60Q34437894-919FC885-DD88-4154-B335-5B5FF632AB06Q34946861-95160EC5-E4EE-4C7A-BED4-BA44B3A4DA4FQ35022931-77BC7276-0283-41E5-A83F-37173854DED1Q35060404-F003F3F4-BE44-49F5-A028-D8AA14E31E57Q36261948-1E982F0A-96DC-47E3-AE6E-CE632672A5E5Q36769825-24BB5AE5-7E4D-4F27-8ADD-F4CDEA4CC2AEQ37409003-8DDAF521-165B-47FB-8E2F-526379B5DE17Q38056312-B61699F7-1789-4B82-802A-A1A0F00D2D7AQ38690199-75DE6E71-81E3-4D45-89BB-85879AF5DAC4Q38740344-487FCC35-AEAF-4813-BA52-E492279AE863Q38917772-F8FDBA57-A02C-4F08-90A9-D4A9D81DB497Q39413648-BFC6D91E-8EE3-4D5F-95A0-5D8D21EEC3A0Q39942126-50E2BD4C-9DE1-46D1-88E4-3DA93D21FEC8Q42071157-204E69BD-586D-4878-9079-967291965AEDQ42320295-BE01F1C1-B580-4287-81E6-8CB235BC284AQ45337013-DFD5193E-704A-4C9A-9256-B0548B6EC7E3Q46315519-879E640D-6400-4F1E-BF25-AAA465E9027FQ48236109-B14AA73D-92E7-4B10-A573-04DB37802BF7Q48294103-DF1BB728-0C0A-4A81-BC04-BD9164283280Q53060403-DCB534CF-9C5B-4E6A-8D2C-EB01DF1E6603Q53153089-5EF5EB5A-1B25-4D25-803F-0F66228CC6E9Q54977077-E167A143-3E45-4FFE-97BB-8111B298C0EBQ59138318-78BC1AC3-6D84-4623-9031-DB84390AD5D5
P2860
NS6180, a new K(Ca) 3.1 channel inhibitor prevents T-cell activation and inflammation in a rat model of inflammatory bowel disease.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
NS6180, a new K(Ca) 3.1 channe ...... of inflammatory bowel disease.
@ast
NS6180, a new K(Ca) 3.1 channe ...... of inflammatory bowel disease.
@en
NS6180, a new K(Ca) 3.1 channe ...... of inflammatory bowel disease.
@nl
type
label
NS6180, a new K(Ca) 3.1 channe ...... of inflammatory bowel disease.
@ast
NS6180, a new K(Ca) 3.1 channe ...... of inflammatory bowel disease.
@en
NS6180, a new K(Ca) 3.1 channe ...... of inflammatory bowel disease.
@nl
prefLabel
NS6180, a new K(Ca) 3.1 channe ...... of inflammatory bowel disease.
@ast
NS6180, a new K(Ca) 3.1 channe ...... of inflammatory bowel disease.
@en
NS6180, a new K(Ca) 3.1 channe ...... of inflammatory bowel disease.
@nl
P2093
P2860
P1476
NS6180, a new K(Ca) 3.1 channe ...... of inflammatory bowel disease
@en
P2093
D P Jenkins
P Christophersen
S Jørgensen
P2860
P304
P356
10.1111/J.1476-5381.2012.02143.X
P407
P577
2013-01-01T00:00:00Z